After CKD develops, frequently prescribed alternatives to TAC include anti-metabolites, such as mycophenolic acid derivatives, and mammalian target of rapamycin (mTOR) inhibitors (Saliba et al., 2011). The gene discussed is MTOR; the disease is chronic kidney disease.